Physician profile
Thomas E Spears
NPI 1700883667
$1,992.99
in general payments reported to CMS, 2019-2025
34 companies · $735 in 2025
The $735 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $35.84 · 2021: $32.83 · 2022: $56.45 · 2023: $507 · 2024: $498 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,716 · Education: $24.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,715.92 |
| Education | $24.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $334.69 | 2024-2025 | Adstiladrin |
| Lundbeck LLC | $151.84 | 2023-2025 | Vyepti |
| Novo Nordisk INC | $150.29 | 2022-2024 | Wegovy |
| Cook Medical LLC | $145.62 | 2025 | Litho 150 |
| Astellas Pharma US INC | $125.78 | 2019-2021 | |
| Abbvie INC. | $123.02 | 2023-2024 | Mavyret, Lupron Depot |
| Takeda Pharmaceuticals U.S.A., INC. | $118.47 | 2023-2024 | Entyvio, Gattex |
| Janssen Biotech, INC. | $113.80 | 2025 | Tremfya |
| Sumitomo Pharma America, INC. | $71.33 | 2023-2025 | Orgovyx |
| Neurelis, INC. | $61.95 | 2023 | Valtoco |
| Coloplast Corp | $47.37 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $42.59 | 2023-2024 | Crexont, Rytary |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.10 | 2023-2025 | Xifaxan |
| Urogen Pharma, INC. | $29.37 | 2025 | |
| Tolmar, INC. | $28.55 | 2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $26.68 | 2025 | Zejula, Jemperli |
| Alexion Pharmaceuticals, INC. | $26.30 | 2025 | Ultomiris |
| Intercept Pharmaceuticals, INC. | $24.90 | 2024 | |
| Neurocrine Biosciences, INC. | $24.48 | 2023 | Ongentys, Ingrezza |
| Celltrion USA INC. | $24.46 | 2024 | Zymfentra |
| Redhill Biopharma INC. | $23.62 | 2023 | |
| Convatec INC. | $23.25 | 2024 | |
| Exact Sciences Corporation | $22.95 | 2025 | Cologuard Collection Kit |
| Ucb, INC. | $21.83 | 2025 | Rystiggo |
| Orphalan INC | $21.76 | 2024 | Cuvrior |
| Tris Pharma INC | $21.41 | 2023 | Dyanavel Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.01 | 2019 | |
| Merck Sharp & Dohme LLC | $20.30 | 2020 | |
| Daiichi Sankyo INC. | $19.79 | 2024 | Injectafer |
| Ardelyx, INC. | $18.88 | 2023 | Ibsrela |
| Boston Scientific Corporation | $18.87 | 2022 | |
| Corium, LLC | $18.66 | 2023 | Azstarys |
| Advanced Respiratory, INC | $17.65 | 2019 | |
| Dynavax Technologies Corporation | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Spears listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.